Isavuconazonium sulfate is the water-soluble prodrug of isavuconazole.
Contra-indicated in patients with familial short QT syndrome.
- TRADE NAME: Cresemba (Astellas)
- INDICATIONS: Invasive aspergillosis, mucormycosis
- SYNONYM: Isavuconazole
- CLASS: Antifungal / antimycotic, Antifungal; triazole, Antimicrobial
- HALF-LIFE: 130 hours
- FDA APPROVAL DATE: 03/06/2015
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Carbamazepine, Ketoconazole, Rifampin, Ritonavir, St John's Wort, Strong CYP3A4 inducers or inhibitors
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 11/17/2024
